Autoimmune necrotizing myositis. Presentation of a clinical case
Abstract
Inflammatory myopathies (IM) or myositis are a heterogeneous group of muscle diseases of rare occurrence. Such diseases are characterized by inflammation of the different components of muscle tissue, which can occur either in isolation or, more commonly, as part of a systemic disorder. Immune-mediated necrotizing myopathies (IMNM) are a type of autoimmune myopathy characterized by proximal muscle weakness, myofiber necrosis with minimal inflammatory cell infiltrate on muscle biopsy and infrequent extramuscular involvement.References
I. Pinal-Fernández L, Casal-Domínguez M, Mammen AL. Immunemediated necrotizing myopathy. Curr Rheumatol Rep 2018; 20(4): 21.
II. Hoogendijk JE, Amato AA, Lecky BR, Choy EH, Lundberg IE, Rose MR, et al. 119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10-12 October 2003, Naarden, The Netherlands. Neuro-muscul Disord 2004; 14(5):337-45. (PubMed: 15099594).
III. Allenbach Y, Mammen AL, Stenzel W, Benveniste O. Immune-mediated necrotizing myopathies working G. 224th ENMC International Workshop: Clinico-sero-pathological classification of immune-mediated necrotizing myopathies Zandvoort, The Netherlands, 14-16 October 2016. Neuromuscul Disord 2017 Most recent classification criteria in IMNM. It includes consensus treatment recommendations for the different IMNM subsets. Neuromuscul Disord. 2018 Jan; 28(1):87-99.
IV. Senecal JL, Raynauld JP, Troyanov Y. A new classification of adult autoimmune myositis (editorial). Arthritis Rheumatol 2017; 69(5):878-84.
V. Christopher-Stine L, Casciola-Rosen LA, Hong G, Chung T, Corse AM, Mammen AL. A novel autoantibody recognizing 200-kd and 100-kd proteins is associated with an immune-mediated necrotizing myopathy. Arthritis Rheum 2010; 62(9):2757-66.
VI. Pinal-Fernández I, Casciola-Rosen LA, Christopher-Stine L, Corse AM, Mammen AL. The prevalence of individual histopathologic features varies according to autoantibody status in muscle biopsies from patients with dermatomyositis. J Rheumatol 2015; 42(8):1448-54.
VII. Paik JJ, Wigley FM, Lloyd TE, Corse AM, Casciola-Rosen L, Shah AA, et al. Spectrum of muscle histopathologic findings in forty-two scleroderma patients with weakness. Arthritis Care Res (Hoboken) 2015; 67(10):1416-25.
VIII. Pinal-Fernández I, Parks C, Werner JL, et al. Longitudinal course of disease in a large cohort of myositis patients with autoantibodies recognizing the signal recognition particle. Arthritis Care Res (Hoboken) 2017; 69(2):263-70.
IX. Allenbach Y, Keraen J, Bouvier AM, et al. High risk of cancer in autoimmune necrotizing myopathies: usefulness of myositis specific antibody. Brain 2016; 139 (Pt 8):2131-5.
X. Suzuki S, Nishikawa A, Kuwana M, et al. Inflammatory myopathy with anti-signal recognition particle antibodies: case series of 100 patients. Orphanet J Rare Dis 2015; 10:61.
XI. Limaye V, Bundell C, Hollingsworth P, et al. Clinical and genetic associations of autoantibodies to 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase in patients with immune-mediated myositis and necrotizing myopathy. Muscle Nerve 2015; 52(2):196-203.
XII. Mastaglia FL. Inflammatory muscle diseases. Neurol India 2008 jul-sep; 56 (3):263.
XIII. Acosta I, Matamala JM, Jara P, et al. Miopatías inflamatorias idiopáticas: una mirada actualizada al diagnóstico y el manejo. Rev Med Chile 2019; Vol 147 (3):342-355.
Copyright (c) 2021 Intellectual property rights: authors. Reproduction rights: Argentine Society of Rheumatology
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
